modelEverolimus

Diagram of Everolimus

Extends from Pharmacolibrary.Drugs.ATC.L.L01EG02.

Information

name:Everolimus
ATC code:L01EG02
route:oral
compartments:2
dosage:10mg
volume of distribution:191L
clearance:8.8L/h
other parameters in model implementation

Everolimus is an orally available mTOR inhibitor used as an anticancer and immunosuppressive agent. It is indicated for the treatment of various cancers, including renal cell carcinoma, breast cancer, neuroendocrine tumors, as well as for prevention of organ transplant rejection. Everolimus is approved by regulatory agencies worldwide and in active clinical use today.

Pharmacokinetics

Pharmacokinetic parameters reported in adult cancer patients. Parameters reflect population pharmacokinetics after oral administration of 10 mg once daily.

References

  1. Combes, FP, et al., & Nedelman, J (2018). Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex. Journal of pharmacokinetics and pharmacodynamics 45(5) 707–719. DOI:10.1007/s10928-018-9600-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29992479

  2. Tanaka, A, et al., & Matsubara, K (2016). Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. Therapeutic drug monitoring 38(6) 663–669. DOI:10.1097/FTD.0000000000000344 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27661398

  3. Moes, DJ, et al., & Guchelaar, HJ (2012). Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clinical pharmacokinetics 51(7) 467–480. DOI:10.2165/11599710-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22624503

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)